Michael V. Miles, PharmD
Title
Director, Neuropharmacology Laboratory
Email
michael.miles@cchmc.org
Phone
513-636-7871
Fax
513-636-1888
Bio
Dr. Miles has been a member of the Division of Pediatric Neurology for over 5 years. He is an experienced clinician and researcher, who has studied the pharmacokinetics and pharmacodynamics of drugs in pediatric populations for much of his career. He has dedicated his clinical and research efforts to improving the efficacy and safety of drug therapy for infants and children. His research is currently focused on the development of new biomarkers and therapeutic agents for patients with mitochondrial diseases.
Credentials
PharmD: University of Texas at Austin, Austin, Texas, 1979.
Specialty Residency: Pediatric Clinical Pharmacy, University of Texas at Austin, Austin, Texas.
Certification: Pharmacy, 1976.
Awards and Honors
- Chairman of the Ohio River Valley Section of the American Association for Clinical Chemistry.
- Distinguished Abstract Award for "Coenzyme Q10 Associations with Metabolic Syndrome" presented by the National Academy of Clinical Biochemistry at the annual meeting of the American Association for Clinical Chemistry, Los Angeles, California, July 2004.
- 2004 Best Poster Award for "Coenzyme Q10 Associations with Metabolic Syndrome" at the annual meeting of the Ohio River Valley Regional Conference of the AACC, Dayton, Ohio, 2004.
- UNC Faculty Council Representative for School of Pharmacy, University of North Carolina at Chapel Hill, 1990-93.
- Health of the Public Scholar, Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, 1989.
Research Grants and Contracts
Comparison of Coenzyme Q10 Bioavailability in Healthy Adults. 2000 – 2001; principal investigator.
Children's Hospital Medical Center Pediatric Pharmacology Research Unit. National Institute of Child Health and Development, National Institutes of Health; 1999 – 2002; co-investigator.
Carbamazepine Kinetics and Metabolism During Pregnancy. CDC/Maternal-Fetal Medicine Unit Network; 2001 – 2003; co-investigator.
Publications, Most Recent
Miles MV, Patterson BJ, Schapiro MB, Hickey FJ, Chalfonte-Evans M, Horn PS, Hotze S: Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial.Pediatric Neurology 2006;(in press).
Jones M, Ryan MA, Miles MV, Tang PH, Fakhoury TA, DeGrauw T, Baumann RJ: Stability of salivary concentrations of the newer antiepileptic drugs in the postal system.Therapeutic Drug Monitoring 2005;27:576-579.
Miles L, Miles MV, Tang PH, Horn PS, Quinlan JG, Wong B, Wenisch A, Bove KE: Ubiquinol: a potential biomarker for tissue energy requirements and oxidative stress.Clinica Chimica Acta 2005;360:87-96.
Miles L, Miles MV, Tang PH, Horn PS, Wong B, DeGrauw T, Morehart P, Bove KE: Coenzyme Q: a potential marker for mitochondrial activity and redox status in skeletal muscle.Pediatric Neurology 2005;32:318-324.
Miles MV, Horn PS, Tang PH, Morrison JA, Miles L, DeGrauw T, Pesce AJ: Age-related changes in plasma coenzyme Q10 concentrations and redox state in apparently healthy children and adults.Clinica Chimica Acta 2004;347:139-144.
Steele PE, Tang PH, DeGrauw AJ, Miles MV: Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases.American Journal of Clinical Pathology 2004;121(Suppl 1):S113-S120.
Tennison M, Ali I, Miles MV, et al: Feasibility and acceptance of salivary monitoring of antiepileptic drugs via the U.S. Postal Service.Therapeutic Drug Monitoring 2004;26:295-299.
Miles MV, Tang P, Ryan MA, et al: Feasibility and limitations of oxcarbazepine monitoring using salivary 10-hydroxy-10-11-dihydro carbazepine (MHD).Therapeutic Drug Monitoring 2004;26:300-304.
Miles MV, Morrison JA, Horn PS, Tang PH, Pesce AJ: Coenzyme Q10 changes are associated with metabolic syndrome.Clinica Chimica Acta 2004;344:173-179.
Tang PH, Miles MV, Miles L, Quinlan J, Wong B, Wenisch A, Bove K: Measurement of reduced and oxidized coenzyme Q9 and coenzyme Q10 levels in mouse tissues by HPLC with coulometric detection.Clinica Chimica Acta 2004;341:173-184.
Ryan M, Grim SA, Miles MV, et al: Correlation of lamotrigine concentrations between serum and saliva.Pharmacotherapy 2003;23(12):1550-1557.
Miles MV, Tang PH, Glauser TA, Ryan MA, Grim SA, Strawsburg RH, deGrauw T, Baumann RJ: Topiramate concentrations in saliva: an alternative to serum monitoring.Pediatric Neurology 2003;29(2):143-147.
Miles MV, Horn P, Morrison JA, et al: Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults.Clinica Chimica Acta 2003;332:123-132.
Grim SA, Ryan M, Miles MV, et al: Correlation of levetiracetam concentrations between serum and saliva.Therapeutic Drug Monitoring 2003;25:61-66.
Professional Organization Memberships
- American Association for Clinical Chemistry
- Ohio River Valley Section of the American Association for Clinical Chemistry
- American Epilepsy Society
Special Interests
Michael V. Miles, PharmD, has a special interest in pediatric pharmacotherapy.
Research Interests
- Pediatric neuropharmacology
Presentations
Miles MV, Morrison JA, Horn PS, Ricciardi R, Harrison HH, Tang PH, Pesce AJ: LPL and NQO1 genotypes are associated with decreased coenzyme Q10 redox ratio in adults with metabolic syndrome: an exploratory study. Presented at the Annual Meeting of the American Association for Clinical Chemistry, July, 2005.
Miles MV, Morrison JA, Horn PS, Tang PH, Pesce AJ: Coenzyme Q10 associations with metabolic syndrome. Presented at the Annual Meeting of the American Association for Clinical Chemistry, July, 2004.
Miles MV, et al: Oxcarbazepine metabolite (MHD) concentration in saliva offers an alternative to serum for therapeutic monitoring. Presented at the Annual Meeting of the American Epilepsy Society, December, 2003.
Miles MV, Horn PS, Morrison JA, et al: Reference intervals for coenzyme Q10 in self-reported healthy adults. Presented at the Annual Meeting of the American Association for Clinical Chemistry, July, 2003.
